FIG. 2. Wild-type (WT) Spike-receptor binding domain (S-RBD) IgG and surrogate virus neutralization test (sVNT) results after COVID-19 vaccination by disease category. A and B show S-RBD IgG and sVNT results respectively in five disease categories (combined, humoral, innate, dysregulation and phagocytic) after 2 doses, while C and D show S-RBD and sVNT results after 3 doses. Geometric means (GM) are shown with centre lines and stated above each column. Limits of detection and quantification (LOD and LOQ) were drawn as grey lines. Number of analyzed available samples (n) are also stated above each column. A and B included 2 patients (one each in combined and innate) who received first 2 doses intradermally and their datapoints were shown as darkened squares. C and D also included 4 patients (1 each in combined, humoral, innate and dysregulation) who received their third dose intradermally and their datapoints were also shown as darkened squares.
Table 2. Antibody responses in IEI patients. * denotes results samples taken after breakthrough infection. Negative S-RBD IgG, WT sVNT and BA.1 sVNT results were imputed as 0.25, 15 and 10 respectively. B – BNT162b2, C – CoronaVac, M (route) – intramuscular, D – intradermal.